Lipigon Pharmaceuticals AB (publ) (STO:LPGO)
Sweden · Delayed Price · Currency is SEK 0.0148
-0.0002 (-1.33%)
Jan 21, 2026, 3:52 PM CET
Lipigon Pharmaceuticals AB Company Description
Lipigon Pharmaceuticals AB (publ), a clinical-stage pharmaceutical company, develops drugs for lipid related diseases in Sweden.
Its product pipeline consists of Lipisense project, which is in phase II for the treatment of severe hypertriglyceridemia disease; Dyslipidemia project, which is in preclinical trial to treat cardiovascular disease and severe hypertriglyceridemia; and CAP project, which is in preclinical trial to treat and prevent lung injury associated with community-acquired pneumonia.
The company has a license agreement with Leaderna for the development of Lipisense. The company was incorporated in 2010 and is based in Umeå, Sweden.
Lipigon Pharmaceuticals AB (publ)
| Country | Sweden |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Johan Liwing |
Contact Details
Address: Tvistevägen 48 C Umeå, 90736 Sweden | |
| Phone | 46 7 06 70 36 75 |
| Website | lipigon.se |
Stock Details
| Ticker Symbol | LPGO |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0015382072 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Johan Liwing | Chief Executive Officer |
| Lars Ohman | Business Development Manager and Chairman |
| Dr. Stefan K. Nilsson | Co-Founder |
| Hugo Petit | Chief Financial Officer |